全文获取类型
收费全文 | 1936篇 |
免费 | 107篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 63篇 |
妇产科学 | 7篇 |
基础医学 | 245篇 |
口腔科学 | 15篇 |
临床医学 | 89篇 |
内科学 | 481篇 |
皮肤病学 | 127篇 |
神经病学 | 116篇 |
特种医学 | 63篇 |
外科学 | 461篇 |
综合类 | 12篇 |
预防医学 | 36篇 |
眼科学 | 38篇 |
药学 | 59篇 |
中国医学 | 1篇 |
肿瘤学 | 235篇 |
出版年
2024年 | 2篇 |
2023年 | 12篇 |
2022年 | 32篇 |
2021年 | 48篇 |
2020年 | 31篇 |
2019年 | 39篇 |
2018年 | 54篇 |
2017年 | 31篇 |
2016年 | 43篇 |
2015年 | 42篇 |
2014年 | 58篇 |
2013年 | 77篇 |
2012年 | 88篇 |
2011年 | 109篇 |
2010年 | 81篇 |
2009年 | 67篇 |
2008年 | 123篇 |
2007年 | 112篇 |
2006年 | 128篇 |
2005年 | 140篇 |
2004年 | 126篇 |
2003年 | 107篇 |
2002年 | 125篇 |
2001年 | 33篇 |
2000年 | 35篇 |
1999年 | 33篇 |
1998年 | 39篇 |
1997年 | 23篇 |
1996年 | 17篇 |
1995年 | 14篇 |
1994年 | 15篇 |
1993年 | 11篇 |
1992年 | 15篇 |
1991年 | 10篇 |
1990年 | 13篇 |
1989年 | 12篇 |
1988年 | 7篇 |
1987年 | 15篇 |
1986年 | 13篇 |
1985年 | 18篇 |
1984年 | 3篇 |
1983年 | 6篇 |
1982年 | 7篇 |
1981年 | 7篇 |
1980年 | 5篇 |
1978年 | 7篇 |
1976年 | 5篇 |
1972年 | 2篇 |
1959年 | 2篇 |
1957年 | 1篇 |
排序方式: 共有2052条查询结果,搜索用时 31 毫秒
81.
Kondo K Kitagawa K Nagai Y Yamagami H Hashimoto H Hougaku H Hori M 《Atherosclerosis》2005,179(1):155-160
Our previous study demonstrated that plasma concentration of high-sensitivity C-reactive protein (hs-CRP) is a marker of carotid atherosclerosis activity. In this study, we investigated whether plasma levels of soluble cell adhesion molecules have potential value to predict atherosclerosis progression. The study included 192 outpatients 40-82 years of age who were treated for traditional risk factor for cardiovascular disease. Patients underwent repeated ultrasonographic evaluation for 53+/-11 months. Severity of atherosclerosis was evaluated by the maximal intimal-medial thickness (max-IMT), plaque number (PN) and plaque score (PS, the sum of all plaque thicknesses). Blood samples were collected for measurement of hs-CRP, soluble intercellular adhesion molecule (sICAM-1) and sP-selectin at the time of baseline examination. The development of atherosclerosis was estimated by the formula: Deltavalue/year=(last value-baseline value)/number of follow-up years. Multivariate linear regression analysis revealed that sICAM-1 was associated with DeltaIMT/year and DeltaPS/year, which was not the case for sP-selectin. sICAM-1 was closely associated with DeltaIMT/year especially in patients with apparent atheromatous plaque. Our results suggested that levels of sICAM-1 might have predictive value of progression of carotid atherosclerosis independently of traditional risk factors and hs-CRP. 相似文献
82.
Comparison of direct sequencing and Invader assay for Y93H mutation and response to interferon‐free therapy in hepatitis C virus genotype 1b
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Kazuhiko Hayashi Masatoshi Ishigami Yoji Ishizu Teiji Kuzuya Takashi Honda Hiroki Kawashima Tetsuya Ishikawa Yoshihiko Tachi Masashi Hattori Yoshiaki Katano Hidemi Goto Yoshiki Hirooka 《Journal of gastroenterology and hepatology》2018,33(1):249-255
Background and Aim
Virologic failure of interferon‐free therapy has been associated with Y93H mutation in the non‐structure 5A region in hepatitis C virus (HCV) genotype 1b, and screening is recommended. A simple assay based on Q‐Invader technology was developed for Y93H mutant screening to reduce cost and effort. The present study sought to compare two methods of detection of Y93H mutation and to evaluate the effect of Y93H mutation on response to interferon‐free therapy.Methods
Y93H mutation was examined in 258 patients with HCV genotype 1b using both direct sequencing analysis and the polymerase chain reaction (PCR)‐Invader assay. Daclatasvir and asunaprevir or ledipasvir and sofosbuvir therapy was administered to 205 patients whose sustained virological responses (SVR) were checked.Results
Hepatitis C virus was detected in 232 of 258 patients by direct sequencing and in 236 of 258 patients by the PCR‐Invader assay. Forty of 231 cases were defined as Y93 mutation by direct sequencing, and 46 of 236 cases were defined as Y93 mutation by the PCR‐Invader assay. SVR of patients who were Y93H by direct sequencing, Y93H by the PCR‐Invader assay, and Y93H by both methods was 62.5%, 82.4%, and 50%, respectively.Conclusions
The sensitivity of the PCR‐Invader assay was similar to that of direct sequencing analysis; however, the PCR‐Invader assay had a better ability to detect minor strains. Combination of the two assays would improve prediction of the response to daclatasvir and asunaprevir, but Y93H mutation had little effect on SVR in ledipasvir and sofosbuvir therapy. 相似文献83.
Kae Kawachi Takeshi Sasaki Ayumi Murakami Takashi Ishikawa Ayako Kito Ikuko Ota Daisuke Shimizu Akinori Nozawa Yoji Nagashima Rikuo Machinami Ichiro Aoki 《Pathology, research and practice》2010
This study aimed at evaluating the usefulness of topoisomerase II alpha (TOP2A) for predicting the effect of anthracycline-based neoadjuvant chemotherapy in breast cancer. The TOP2A status was examined using fluorescent in situ hybridization (FISH) in 14 pre-chemotherapeutic breast cancer tissues, and was also assessed by immunohistochemistry (IHC) in 14 pairs of pre- and post-chemotherapeutic breast cancer specimens. TOP2A gene aberration by IHC tended to show a correlation with pathological responses but this was not statistically significant (p=0.060). On the other hand, the low TOP2A/CEP17 ratio correlated with good pathological responses (p=0.012). TOP2A overexpression was not significantly associated with response (p=0.580). Our results thus suggest that the TOP2A/CEP17 ratio may be a useful predictor of the effects of anthracycline-based neoadjuvant chemotherapy in breast cancer. 相似文献
84.
Anri Sawada Kohei Unagami Shigeru Horita Kunio Kawanishi Masayoshi Okumi Sekiko Taneda Hideki Ishida Motoshi Hattori Kazunari Tanabe Kazuho Honda Keiko Uchida Akira Shimizu Junki Koike Kosaku Nitta Yoji Nagashima 《Pathology international》2019,69(11):655-660
Here, we report the case of a patient with renal allograft with full‐house immunofluorescence staining in the zero‐hour biopsy. Full‐house immunofluorescence staining is a well‐known characteristic of lupus nephritis. Previous studies have reported patients with full‐house immunofluorescence staining, but without other symptoms or serological findings; this condition is referred to as full‐house nephropathy. We identified only one case out of 2203 zero‐hour biopsies over 13 years. Zero‐hour biopsy presented no glomerular changes but showed full‐house immunofluorescence staining. Electron microscopy revealed a nonorganized electron‐dense deposit mainly in the mesangial lesion. Systemic lupus erythematosus (SLE)‐associated antibodies were negative, and complement deficiency was not observed in the donor patients. Deposition of immunoglobulin and complement levels markedly decreased within 1–3 years post transplantation. Neither donor nor recipient developed clinical or biological features of SLE; they showed good renal prognosis. 相似文献
85.
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis,erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week,open‐label,phase 3 study (UNCOVER‐J)
下载免费PDF全文
![点击此处可从《The Journal of dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Hidehisa Saeki Hidemi Nakagawa Ko Nakajo Taeko Ishii Yoji Morisaki Takehiro Aoki Gregory S. Cameron Olawale O. Osuntokun the Japanese Ixekizumab Study Group 《The Journal of dermatology》2017,44(4):355-362
Psoriasis, a chronic, immune‐mediated skin disease characterized by red, scaly plaques, affects approximately 0.3% of the population in Japan. The aim of this open‐label study was to evaluate the long‐term efficacy and safety of ixekizumab, a humanized, anti‐interleukin‐17A monoclonal antibody, in Japanese patients with plaque psoriasis (n = 78, including 11 psoriatic arthritis), erythrodermic psoriasis (n = 8) and generalized pustular psoriasis (n = 5). Ixekizumab was administrated s.c. at baseline (week 0, 160 mg), from weeks 2 to 12 (80 mg every 2 weeks), and from weeks 16 to 52 (80 mg every 4 weeks). At week 52, 92.3% of patients with plaque psoriasis achieved Psoriasis Area and Severity Index (PASI) 75, 80.8% achieved PASI 90, 48.7% achieved PASI 100, and 52.6% had remission of plaques (by static Physician Global Assessment, sPGA [0]). Difficult to treat areas of psoriasis (nail or scalp) also responded to ixekizumab. All patients with psoriatic arthritis who were assessed (5/5) achieved an American College of Rheumatology 20 response. Most patients with erythrodermic psoriasis or generalized pustular psoriasis responded to ixekizumab and the clinical outcome was maintained over 52 weeks (75% and 60% of patients achieved sPGA [0, 1] at week 52, respectively). Mostly mild or moderate treatment‐emergent adverse events were reported by 79 of 91 patients; the most common were nasopharyngitis, eczema, seborrheic dermatitis, urticaria and injection site reactions. In conclusion, 52‐week ixekizumab treatment was efficacious and well tolerated in Japanese patients with plaque psoriasis. Efficacy was also observed in patients with erythrodermic psoriasis, generalized pustular psoriasis and psoriatic arthritis. 相似文献
86.
Kawahara H Hirai K Watanabe K Kashiwagi H Yamazaki Y Yanaga K 《International surgery》2007,92(1):34-36
Conventional functional end-to-end anastomosis (FEEA) is not indicated for left hemicolectomy, sigmoidectomy, and anterior resection. However, our original anastomosis with stapling devices (SFEEA) can be performed at any site in the intestine. We report our novel surgical technique compared with the double stapling technique (DST). Between January 2001 and August 2003, anterior resection with stapling devices was performed in 74 patients (DST, 54; SFEEA, 20). The SEEEA group was greater than the DST group in operation time and significant intraoperative blood loss. In the DST group, two postoperative complications (3.7%) occurred (leakage and stenosis). On the other hand, no complications were noted in the SFEEA group. Our novel technique for colorectal anastomosis, SFEEA, allows safe, wide, physiological, and clean anastomosis compared with FEEA. 相似文献
87.
SAP-1 is a microvillus-specific protein tyrosine phosphatase that modulates intestinal tumorigenesis
Hisanobu Sadakata Hideki Okazawa Takashi Sato Yana Supriatna Hiroshi Ohnishi Shinya Kusakari Yoji Murata Tomokazu Ito Uichi Nishiyama Takashi Minegishi Akihiro Harada Takashi Matozaki 《Genes to cells : devoted to molecular & cellular mechanisms》2009,14(3):295-308
SAP-1 (PTPRH) is a receptor-type protein tyrosine phosphatase (RPTP) with a single catalytic domain in its cytoplasmic region and fibronectin type III-like domains in its extracellular region. The cellular localization and biological functions of this RPTP have remained unknown, however. We now show that mouse SAP-1 mRNA is largely restricted to the gastrointestinal tract and that SAP-1 protein localizes to the microvilli of the brush border in gastrointestinal epithelial cells. The expression of SAP-1 in mouse intestine is minimal during embryonic development but increases markedly after birth. SAP-1-deficient mice manifested no marked changes in morphology of the intestinal epithelium. In contrast, SAP-1 ablation inhibited tumorigenesis in mice with a heterozygous mutation of the adenomatous polyposis coli gene. These results thus suggest that SAP-1 is a microvillus-specific RPTP that regulates intestinal tumorigenesis. 相似文献
88.
Kazunori Murai Shugo Kowata Tadashi Shimoyama Akiko Yashima‐Abo Yukiteru Fujishima Shigeki Ito Yoji Ishida 《European journal of haematology》2014,93(4):290-296
Bortezomib is a potent proteasome inhibitor that has been extensively used to treat multiple myeloma. One of the most common grade 3 adverse events is cyclic thrombocytopenia. In this study, we studied the mechanism by which bortezomib induces thrombocytopenia in a mouse model. After the intravenous administration of bortezomib (2.5 mg/kg) via tail vein, platelet counts significantly decreased on days 2–4 and recovered to the normal range on day 6. Bortezomib (2.5 mg/kg) injected into mice in vivo did not affect colony‐forming unit‐megakaryocytes (CFU‐Mk) or megakaryocytes in the bone marrow. However, proplatelet formation (PPF) significantly decreased on days 2 and 4, after bortezomib administration to mice. Meanwhile, CFU‐Mk formation and the ploidy distribution of cultured megakaryocytes in vitro were not affected by bortezomib used at concentrations of ≤1 ng/mL. The PPF of megakaryocytes in vitro significantly decreased with 0.1, 1, 10, and 100 ng/mL bortezomib. Considering the bortezomib concentration in clinical studies, these data strongly suggest that decreased PPF activity induces thrombocytopenia. To elucidate the mechanism behind decreased PPF, Western blot was performed. Activated Rho expression increased after the incubation of murine platelets with bortezomib. Decreased PPF activity was eliminated by the addition of Y27632, a Rho kinase inhibitor, in vitro. Given that the Rho/Rho kinase pathway is a negative regulator of PPF, bortezomib increases activated Rho, inducing decreased PPF, which results in decreased platelet count. 相似文献
89.
Yoji Likura M.D. Masaru Kishida M.D. Akira Akasawa M.D. Toshikazu Nagakura M.D. Ken-ichi Akimoto M.D. Hirohisa Saito M.D. Niroku Koya M.D. Akiyoshi Sasamoto M.D. 《Pediatrics international》1990,32(2):216-219
The treatment of status asthmaticus is one of the most important factors in controlling the patient with asthma attacks. We have studied hormone changes in status asthmaticus and considered what is the best treatment in the asthma attack condition in children. Antidiuretic hormone (ADH), renin activity, and aldosterone activity are elevated in severe asthma attack conditions, and these high levels are correlated with high levels in Wood's clinical score. It is theoretical that patients with dehydration and respiratory failure show such elevation in hormones, and it is well known that under such conditions β2 -stimulant enhances renin production. From our study, it is concluded that β2 2 -stimulant subcutaneous injection must be considered in status asthmaticus. In children, amminophylline i.v. drip therapy may be one of the best treatments in status asthmaticus. 相似文献
90.